Fortive’s second quarter saw a negative market reaction as management attributed flat sales and operating margin pressure to late-quarter demand softness linked to tariffs, constrained U.S. government spending, and evolving healthcare policy. CEO Olumide Soroye called the quarter "pivotal" as the company completed the spin-off of Precision Technologies, but revenue fell below internal expectations due to deferred purchases in professional instrumentation and healthcare equipment. CFO Mark Okerstrom also cited a "chilling effect" in government procurement activity, leading to higher backlog and project delays. Management’s tone was notably cautious, emphasizing operational resilience amid these external pressures.
Is now the time to buy FTV? Find out in our full research report (it’s free).
Fortive (FTV) Q2 CY2025 Highlights:
- Revenue: $1.02 billion vs analyst estimates of $1.01 billion (flat year on year, in line)
- Adjusted EPS: $0.90 vs analyst estimates of $0.59 (51.9% beat)
- Adjusted EBITDA: $288.4 million vs analyst estimates of $286.2 million (28.4% margin, 0.8% beat)
- Management lowered its full-year Adjusted EPS guidance to $2.55 at the midpoint, a 34.6% decrease
- Operating Margin: 16.7%, down from 17.9% in the same quarter last year
- Organic Revenue was flat year on year vs analyst estimates of flat growth (36.6 basis point miss)
- Market Capitalization: $16.12 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Fortive’s Q2 Earnings Call
- Julian Mitchell (Barclays) asked about the Q3 and Q4 operating cadence and the drivers behind the expected profit rebound. CFO Mark Okerstrom explained that typical seasonality, full implementation of tariff countermeasures, and a lower tax rate would support a sequential EPS increase in Q4.
- Nigel Coe (Wolfe Research) pressed for clarity on segment-specific trends and why Advanced Healthcare Solutions (AHS) would not see a quicker recovery from deferred equipment orders. CEO Olumide Soroye highlighted tough year-over-year comparisons for AHS and a cautious outlook for hospital capital spending.
- Stephen Tusa (JPMorgan) questioned the move to annual, rather than quarterly, organic growth guidance. Okerstrom said this approach was designed to simplify disclosures and allow management more flexibility, though acknowledged feedback that more granular guidance may be preferred.
- Scott Davis (Melius Research) asked about the distraction from the spin-off and leadership changes. Soroye stated that most spin-related disruption was contained to the corporate level, with operating teams maintaining focus and resiliency despite late-quarter sales challenges.
- Joe Giordano (TD Cowen) inquired about the potential for hospitals to shift toward single-use equipment in response to reimbursement pressures. Soroye responded that hospitals remain focused on operating room efficiency and are likely to continue investing in advanced, reusable devices aligned with higher-value procedures.
Catalysts in Upcoming Quarters
Going forward, the StockStory team will be tracking (1) the pace at which deferred orders in Fluke and Gordian convert into realized sales, (2) stabilization in healthcare equipment procurement as hospitals adapt to new reimbursement policies, and (3) the effectiveness of tariff mitigation strategies in restoring margin stability. Progress on bolt-on acquisitions and execution of the Fortive Accelerated strategy will also serve as important indicators of management’s ability to navigate macro and policy headwinds.
Fortive currently trades at $47.25, down from $50.89 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
